Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Inositol monophosphatase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0045 | 0.3023 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0045 | 0.3023 | 0.5 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0045 | 0.3023 | 0.5 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.3023 | 0.5 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.3023 | 0.5 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0045 | 0.3023 | 0.5 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0045 | 0.3023 | 0.5 |
Loa Loa (eye worm) | lethal(1)discs large-1 tumor suppressor | 0.0071 | 0.7825 | 1 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0045 | 0.3023 | 0.5 |
Echinococcus multilocularis | disks large 3 | 0.0075 | 0.8596 | 1 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.004 | 0.2165 | 0.5 |
Mycobacterium tuberculosis | Inositol-1-monophosphatase SuhB | 0.004 | 0.2165 | 0.5 |
Onchocerca volvulus | 0.0032 | 0.0771 | 0.5 | |
Schistosoma mansoni | cell polarity protein | 0.0075 | 0.8596 | 1 |
Schistosoma mansoni | inositol monophosphatase | 0.0045 | 0.3023 | 0.3517 |
Echinococcus granulosus | disks large 3 | 0.0075 | 0.8596 | 1 |
Schistosoma mansoni | inositol monophosphatase | 0.0045 | 0.3023 | 0.3517 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.3023 | 0.5 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.3023 | 0.5 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0045 | 0.3023 | 0.5 |
Brugia malayi | Inositol-1 | 0.0045 | 0.3023 | 0.244 |
Loa Loa (eye worm) | guanylate kinase | 0.0062 | 0.624 | 0.67 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.02 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 50.1187 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.